+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASSF1 Polymorphisms in Cancer

RASSF1 Polymorphisms in Cancer

Molecular Biology International 2012: 365213-365213

Ras association domain family 1A (RASSF1A) is one of the most epigenetically silenced elements in human cancers. Localized on chromosome 3, it has been demonstrated to be a bone fide tumor suppressor influencing cell cycle events, microtubule stability, apoptosis, and autophagy. Although it is epigenetically silenced by promoter-specific methylation in cancers, several somatic nucleotide changes (polymorphisms) have been identified in RASSF1A in tissues from cancer patients. We speculate that both nucleotide changes and epigenetic silencing result in loss of the RASSF1A tumor suppressor function and the appearance of enhanced growth. This paper will summarize what is known about the origin of these polymorphisms and how they have helped us understand the biological role of RASSF1A.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333467

Download citation: RISBibTeXText

PMID: 22701175

DOI: 10.1155/2012/365213

Related references

The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China. Journal of Huazhong University of Science and Technology. Medical Sciences 29(5): 646-649, 2013

Molecular pathology of the RASSF1 gene in colorectal cancer. Virchows Archiv 443(3): 364, September, 2003

Prognostic value of RASSF1 promoter methylation in prostate cancer. Journal of Urology 192(6): 1849-1855, 2015

High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer. Plos One 4(5): E5231-E5231, 2009

High-resolution melting-based quantitative analysis of RASSF1 methylation in breast cancer. Medicina 49(2): 78-83, 2014

Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer. Medicina 47(3): 147-153, 2011

GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Molecular Biology Reports 40(10): 5541-5550, 2014

Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. Journal of Cancer Research and Clinical Oncology 140(11): 1849-1861, 2015

Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics 6(12): 1413-1424, 2012

Expression and mutation analysis of RASSF1, a newly identified putative tumor suppressor at 3p21, in human bladder cancer. Journal of Urology 165(5 Supplement): 118, 2001

PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. International Journal of Cancer 126(7): 1630-1639, 2010

RETRACTED ARTICLE: Impact of Toll-Like Receptors 2/3/4/9, IL-1-α/β and TNF-α Polymorphisms in Cervical Cancer Susceptibility in Tunisia : Genetic polymorphisms implicated in the occurence of Cervical Cancer. Pathology Oncology Research, 2014

Comparative analysis of interactions of RASSF1-10. Advances in Biological Regulation 53(2): 190-201, 2013

Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. Journal of Biological Chemistry 275(46): 35669-35672, 2000

The expression and clinical significance of suppressor gene RASSF1 in gliomas. Journal of China Medical University 37(2): 245-247, 2008